| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Medicine Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20892
Human ovarian cancer cell lines with stable cisplatin resistance have been developed by chronic exposure of the parent cisplatin-sensitive A2780 line to increasing concentrations of cisplatin. 2780CP8 (CP8 refers to this cell line's growth in medium containing 8 µM cisplatin) has several clonal cytogenetic abnormalities but lacks homogeneously staining regions or double-minute chromosomes. It has a significantly greater monolayer growth rate, cloning efficiency in agarose, and total glutathione content compared to the A2780 line, but similar activities of several glutathione-dependent enzymes. The 2780CP8 subline is 7.3-fold resistant to cisplatin compared to the A2780 line, as well as cross-resistant to irradiation and melphalan. It is not cross-resistant to Adriamycin, but this develops with increased cisplatin resistance (14-fold) obtained by further cisplatin exposure of 2780CP8. Of the cisplatin analogues tested which are of current clinical interest, carboplatin, iproplatin, and tetraplatin, only the latter is more cytotoxic than cisplatin in the A2780 and 2780CP8 lines. The 2780CP8 subline is also cross-resistant to these analogues in the relative order carboplatin > iproplatin > tetraplatin (most to least cross-resistant). Treatment of a highly cisplatin resistant cell line (2780CP8) with either melphalan or cisplatin was associated with a significant increase in [3H]thymidine incorporation into DNA in the presence of 10 mM hydroxyurea compared with the parent sensitive cell line which showed essentially no capacity to repair DNA damage by these drugs. A2780 and its cisplatin-resistant cell lines may thus be useful in studying drug resistance mechanisms, in screening new drugs for activity (especially against drug resistant tumors), and in formulating induction and salvage therapies for ovarian cancer.
1 These data were presented, in part, at the 76th Annual Meeting of the American Association for Cancer Research, Houston, TX (1), and the 77th Annual Meeting, Los Angeles, CA.
2 Present address: Division of Hematology/Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210.
3 To whom requests for reprints should be addressed, at Medicine Branch, National Cancer Institute, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892.
Received 3/27/86. Revised 7/22/86. Revised 10/ 9/86. Accepted 10/15/86.
This article has been cited by other articles:
|
|
 |
|
  M. Muscolini, R. Cianfrocca, A. Sajeva, S. Mozzetti, G. Ferrandina, A. Costanzo, and L. Tuosto Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells Mol. Cancer Ther., June 1, 2008; 7(6): 1410 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Witham, M. R. Valenti, A. K. De-Haven-Brandon, S. Vidot, S. A. Eccles, S. B. Kaye, and A. Richardson The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin Clin. Cancer Res., December 1, 2007; 13(23): 7191 - 7198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Pisano, L Vesci, R Fodera, F. Ferrara, C Rossi, M De Cesare, V Zuco, G Pratesi, R Supino, and F Zunino Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models Ann. Onc., September 1, 2007; 18(9): 1500 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kasparkova, O. Novakova, O. Vrana, F. Intini, G. Natile, and V. Brabec Molecular Aspects of Antitumor Effects of a New Platinum(IV) Drug Mol. Pharmacol., November 1, 2006; 70(5): 1708 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Abbosh, J. S. Montgomery, J. A. Starkey, M. Novotny, E. G. Zuhowski, M. J. Egorin, A. P. Moseman, A. Golas, K. M. Brannon, C. Balch, et al. Dominant-Negative Histone H3 Lysine 27 Mutant Derepresses Silenced Tumor Suppressor Genes and Reverses the Drug-Resistant Phenotype in Cancer Cells Cancer Res., June 1, 2006; 66(11): 5582 - 5591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Kelly, A. B. Alvero, R. Chen, D.-A. Silasi, V. M. Abrahams, S. Chan, I. Visintin, T. Rutherford, and G. Mor TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer. Cancer Res., April 1, 2006; 66(7): 3859 - 3868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Alvero, W. Chen, A. C. Sartorelli, P. Schwartz, T. Rutherford, and G. Mor Triapine (3-aninopyridine-2-carboxaldehyde thiosemicarbazone) Induces Apoptosis in Ovarian Cancer Cells Reproductive Sciences, February 1, 2006; 13(2): 145 - 152. [Abstract] [PDF]
|
|
|
|
|
|
K. A. Strait, C. T. Warnick, C. D. Ford, B. Dabbas, E. H. Hammond, and S. J. Ilstrup Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad Mol. Cancer Ther., April 1, 2005; 4(4): 603 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anderson, K. A. Lawson, M. Simmons-Menchaca, L. Sun, B. G. Sanders, and K. Kline {alpha}-TEA Plus Cisplatin Reduces Human Cisplatin-Resistant Ovarian Cancer Cell Tumor Burden and Metastasis Experimental Biology and Medicine, December 1, 2004; 229(11): 1169 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De Cesare, G. Pratesi, S. Veneroni, R. Bergottini, and F. Zunino Efficacy of the Novel Camptothecin Gimatecan against Orthotopic and Metastatic Human Tumor Xenograft Models Clin. Cancer Res., November 1, 2004; 10(21): 7357 - 7364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Anderson, M. Simmons-Menchaca, K. A. Lawson, J. Atkinson, B. G. Sanders, and K. Kline Differential Response of Human Ovarian Cancer Cells to Induction of Apoptosis by Vitamin E Succinate and Vitamin E Analogue, {alpha}-TEA Cancer Res., June 15, 2004; 64(12): 4263 - 4269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Flick, D. O'Malley, T. Rutherford, S. Rodov, M. Kamsteeg, X.-Y. Hao, P. Schwartz, B. M. Kacinski, and G. Mor Apoptosis-Based Evaluation of Chemosensitivity in Ovarian Cancer Patients Reproductive Sciences, May 1, 2004; 11(4): 252 - 259. [Abstract] [PDF]
|
|
|
|
|
|
N. J. Curtin, L.-Z. Wang, A. Yiakouvaki, S. Kyle, C. A. Arris, S. Canan-Koch, S. E. Webber, B. W. Durkacz, H. A. Calvert, Z. Hostomsky, et al. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells Clin. Cancer Res., February 1, 2004; 10(3): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Smith, B. M. Booker, P. Creaven, R. Perez, and L. Pendyala Pharmacokinetics and Pharmacodynamics of Mesna-Mediated Plasma Cysteine Depletion J. Clin. Pharmacol., December 1, 2003; 43(12): 1324 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Y. F. Lee, R. Borzilleri, C. R. Fairchild, S.-H. Kim, B. H. Long, C. Reventos-Suarez, G. D. Vite, W. C. Rose, and R. A. Kramer BMS-247550: A Novel Epothilone Analog with a Mode of Action Similar to Paclitaxel but Possessing Superior Antitumor Efficacy Clin. Cancer Res., May 1, 2001; 7(5): 1429 - 1437. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. S. Lazo, K. Tamura, A. Vogt, J.-K. Jung, S. Rodriguez, R. Balachandran, B. W. Day, and P. Wipf Antimitotic Actions of a Novel Analog of the Fungal Metabolite Palmarumycin CP1 J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 364 - 371. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Li, Q. Feng, J.-M. Kim, D. Schneiderman, P. Liston, M. Li, B. Vanderhyden, W. Faught, M. F. K. Fung, M. Senterman, et al. Human Ovarian Cancer and Cisplatin Resistance: Possible Role of Inhibitor of Apoptosis Proteins Endocrinology, January 1, 2001; 142(1): 370 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heise, M. Lemmon, and D. Kirn Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration Clin. Cancer Res., December 1, 2000; 6(12): 4908 - 4914. [Abstract] [Full Text]
|
|
|
|
|
|
L. Pendyala, P. J. Creaven, G. Schwartz, N. J. Meropol, W. Bolanowska-Higdon, J. Zdanowicz, M. Murphy, and R. Perez Intravenous Ifosfamide/Mesna Is Associated with Depletion of Plasma Thiols without Depletion of Leukocyte Glutathione Clin. Cancer Res., April 1, 2000; 6(4): 1314 - 1321. [Abstract] [Full Text]
|
|
|
|
|
|
T. Furui, R. LaPushin, M. Mao, H. Khan, S. R. Watt, M.-A. V. Watt, Y. Lu, X. Fang, S. Tsutsui, Z. H. Siddik, et al. Overexpression of Edg-2/vzg-1 Induces Apoptosis and Anoikisin Ovarian Cancer Cells in a Lysophosphatidic Acid-independent Manner Clin. Cancer Res., December 1, 1999; 5(12): 4308 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Leyland-Jones, L. R. Kelland, K. R. Harrap, and L. R. Hiorns Genomic Imbalances Associated with Acquired Resistance to Platinum Analogues Am. J. Pathol., July 1, 1999; 155(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Zou, L. A. Morford, C. Chougnet, A. R. Dix, A. G. Brooks, N. Torres, J. D. Shuman, J. E. Coligan, W. H. Brooks, T. L. Roszman, et al. Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) That Alters Monocyte Cytokine Profile and Surface Markers J. Immunol., April 15, 1999; 162(8): 4882 - 4892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Li, K. Gardner, L. Zhang, B. Tsang, F. Bostick-Bruton, and E. Reed Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells J. Biol. Chem., September 4, 1998; 273(36): 23419 - 23425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Jones, J. Turner, A. J. McIlwrath, R. Brown, and C. Dive Cisplatin- and Paclitaxel-Induced Apoptosis of Ovarian Carcinoma Cells and the Relationship between Bax and Bak Up-Regulation and the Functional Status of p53 Mol. Pharmacol., May 1, 1998; 53(5): 819 - 826. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Kowalski, P. Giannakakou, S. P. Gunasekera, R. E. Longley, B. W. Day, and E. Hamel The Microtubule-Stabilizing Agent Discodermolide Competitively Inhibits the Binding of Paclitaxel (Taxol) to Tubulin Polymers, Enhances Tubulin Nucleation Reactions More Potently than Paclitaxel, and Inhibits the Growth of Paclitaxel-Resistant Cells Mol. Pharmacol., October 1, 1997; 52(4): 613 - 622. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Kowalski, P. Giannakakou, and E. Hamel Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (TaxolŽ) J. Biol. Chem., January 24, 1997; 272(4): 2534 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Drummond, A. Anthoney, R. Brown, and P. Modrich Cisplatin and Adriamycin Resistance Are Associated with MutLalpha and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line J. Biol. Chem., August 16, 1996; 271(33): 19645 - 19648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yokomizo, K. Kohno, M. Wada, M. Ono, C. S. Morrow, K. H. Cowan, and M. Kuwano Markedly Decreased Expression of Glutathione S-Transferase [IMAGE] Gene in Human Cancer Cell Lines Resistant to Buthionine Sulfoximine, an Inhibitor of Cellular Glutathione Synthesis J. Biol. Chem., August 18, 1995; 270(33): 19451 - 19457. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
